Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity

Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482
Authors:
X Hu
Shoiab Bukhari
Carly Tymm
Kieran Adam
Shalom Lerrer
Brian S. Henick
Robert Winchester
Adam Mor
Affiliated Authors:
X Hu
Shoiab Bukhari
Carly Tymm
Kieran Adam
Shalom Lerrer
Brian S. Henick
Robert Winchester
Adam Mor
Columbia Affiliation:
Subjects:
Neoplasms (MeSH)
Cancer Immunotherapy (OpenAlex Topic)
Neuroblastoma Research and Treatment (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Author Keywords:
immune checkpoint inhibitors
immunotherapy
nivolumab
ipilimumab
t-lymphocytes
Grants:
R21CA231277 (NIH – National Cancer Institute)
R01AI150597 (NIH – National Institute of Allergy and Infectious Diseases)
R01AI175498 (NIH – National Institute of Allergy and Infectious Diseases)
R01AI125640 (NIH – National Institute of Allergy and Infectious Diseases)
T32GM145440 (NIH – National Institute of General Medical Sciences)
S10OD030282 (NIH – Office of the Director, National Institutes of Health)
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2023-008482
PMID:
38519059
DOI:
10.1136/jitc-2023-008482
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created:

Report an error in this record